

Polygenic Risk Scores for Asthma and Allergic Disease Predict COVID-19 Severity in 9/11

Responders

Monika A. Waszczuk, PhD¹, Olga Morozova, PhD², Elizabeth Lhuillier, MD^{3,4}, Anna R. Docherty, PhD^{5,6}, Andrey A. Shabalin, PhD^{5,6}, Xiaohua Yang, MS⁴, Melissa A. Carr, Ms³, Sean A. P. Clouston, PhD⁷, Roman Kotov, PhD⁸, and Benjamin J. Luft, MD^{3,4}

¹ Department of Psychology, Rosalind Franklin University of Medicine and Science, North Chicago, IL

² Department of Public Health Sciences, Biological Sciences Division, University of Chicago, Chicago, IL

³ World Trade Center Health and Wellness Program, Stony Brook University, Stony Brook, NY

⁴ Department of Medicine, Stony Brook University, Stony Brook, NY

⁵ Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, UT

⁶ Huntsman Mental Health Institute, Salt Lake City, UT

⁷ Program in Public Health, Department of Family, Population, and Preventive Medicine, Stony Brook University, Stony Brook, NY

⁸ Department of Psychiatry, Stony Brook University, Stony Brook, NY

Corresponding author:

Benjamin J. Luft, MD, Edmund D. Pellegrino Professor of Medicine and Director, WTC Health Program, State University of New York at Stony Brook, Department of Medicine, SUNY at Stony Brook, Nicolls Road, HSC T-16, Room 082A, Stony Brook, New York 11794-8166. Phone number: (631) 444-6436; Fax Number: (631) 444-8943; Email: Benjamin.Luft@stonybrookmedicine.edu

ORCID IDs:

Monika A. Waszczuk: 0000-0003-1775-1970

Olga Morozova: 0000-0001-7606-8413

Anna R. Docherty: 0000-0001-7139-7007

Andrey A. Shabalin: 0000-0003-0309-6821

Melissa Carr: 0000-0002-0870-6628

Roman Kotov: 0000-0001-9569-8381

Benjamin J. Luft: 0000-0001-9008-7004

Abstract: 248 words

Manuscript: 3,484 words

Tables: 4

References: 29

Abstract

Background. Genetic factors contribute to individual differences in the severity of coronavirus disease 2019 (COVID-19). A portion of genetic predisposition can be captured using polygenic risk scores (PRS). Relatively little is known about the associations between PRS and COVID-19 severity or post-acute COVID-19 in community-dwelling individuals. **Methods.** Participants in this study were 983 World Trade Center responders infected for the first time with SARS-CoV-2 (mean age at infection=56.06, standard deviation [SD]=7.37, 918 (93.4%) male, 813 (82.7%) European ancestry). Seventy-five (7.6%) responders were in the severe COVID-19 category, that included hospitalization and other adverse outcomes; 306 (31.1%) reported at least one post-acute COVID-19 symptom at the 4-week follow-up. Analyses were adjusted for population stratification and demographic covariates. **Findings.** In responders with European ancestry, the asthma PRS was associated with severe COVID-19 category (odds ratio [OR]=1.61, 95% confidence interval: 1.17-2.21) and more severe COVID-19 symptomatology ($\beta=.09$, $p=.01$), independently of respiratory disease diagnosis. The allergic disease PRS similarly associated with severe COVID-19 category (OR=1.97, [1.26-3.07]). The PRS for COVID-19 hospitalization was associated with the risk of severe COVID-19 category (OR=1.35, [1.01-1.82]), but this association was smaller than for the asthma PRS. PRS for coronary artery disease and type II diabetes were not associated with COVID-19 severity. **Interpretation.** Taken together, the results indicate that recently developed polygenic biomarkers for asthma, allergic disease, and COVID-19 hospitalization capture some of the individual differences in severity and clinical course of COVID-19 illness in a community population. **Funding.** National Institute for Occupational Safety and Health, CDC.

Keywords: 9/11 responders; COVID-19; SARS-CoV-2; post-acute COVID-19 syndrome; polygenic risk score; asthma; allergic disease

Polygenic Risk Scores for Asthma and Allergic Disease Predict COVID-19 Severity in 9/11

Responders

Coronavirus disease 2019 (COVID-19) is caused by an infection by the severe acute respiratory syndrome coronavirus (SARS-CoV-2) and remains a pandemic in the US and globally¹. COVID-19 invades the respiratory and other crucial systems in the body, varying widely in severity, from asymptomatic presentation to severe outcomes including hospitalization or death. Moreover, at least one-third of individuals with COVID-19 develop post-acute COVID-19 syndrome², which consists of residual respiratory, fatigue, central nervous system, and musculoskeletal symptoms that persist at least four weeks after initial symptom onset^{3,4}. Despite vaccination efforts, the potentially severe and chronic outcomes of COVID-19 necessitate a better characterization of individuals at elevated risk for clinically significant disease outcomes.

Across a range of studies, COVID-19 severity was found to be associated with clinical risk factors such as older age, male sex, smoking, respiratory illness, cardiovascular disease, and immunocompromised status⁵⁻⁷. Moreover, a person's own genetic factors critically affect individual differences in COVID-19 disease severity⁸. Large-scale, population-based genome-wide association studies (GWAS) indicate that multiple common genetic variants can contribute to COVID-19 symptom severity after infection⁹. Genes that emerged from GWAS strongly associated with severe COVID-19 progression are involved in immune response and lung disease pathology. The individual variants associated with disease severity in the discovery GWAS have minor effects, but cumulatively they explain a substantial proportion of genetic variation in response to the virus. Common variants can be collapsed into a polygenic risk score (PRS) to improve the prediction of at-risk patients in an independent cohort. For each individual, the number of risk alleles carried at each variant (0, 1, or 2) can be summed and weighted by its effect size, resulting in a single score of each individual's genetic vulnerability to COVID-19 severity.

COVID-19 PRS have shown to predict increased risk of morbidity and mortality due to COVID-19 in several independent samples and across ancestries, with PRS outperforming individual genetic variants and providing information over and above established risk factors¹⁰⁻¹³. While the COVID-19 PRS was designed to capture all genes associated with the severity of COVID-19, the study relied partially on the UK Biobank cohort, which has limited phenotypic information on COVID-19 disease and exposure status of controls. It is therefore plausible that other PRS capture genetic vulnerability to other conditions, such as asthma or coronary artery disease, that might also predict COVID-19 symptom severity or COVID-19 clinical course, although empirical evidence is limited. For example, only one published study has reported no association between asthma PRS and severe COVID-19¹⁴, but no other studies to our knowledge have examined post-acute COVID-19 symptoms.

Therefore, the present study translated genetic discoveries in COVID-19 host genetics to an independent, well-characterized patient population with a full range of COVID-19 severity. Responders to the World Trade Center (WTC) attacks on September 11, 2001 are a cohort with detailed prospective health data, including information on COVID-19 infection, symptom severity, and follow-up outcomes. Our team has previously demonstrated that younger and employed responders were at a higher risk of being infected with the SARS-CoV-2 virus¹⁵. Among those who experienced infection, a pre-existing obstructive airway disease diagnosis predicted an elevated risk for a more severe COVID-19 presentation². The risk of developing post-acute COVID-19 sequelae was similarly elevated in responders with respiratory problems as well as heart disease, over and above the risk conferred by the COVID-19 severity itself. While respiratory and other chronic conditions are associated with toxic exposures during the 9/11 disaster, some of the individual differences in post-exposure outcomes in 9/11 responders can be attributed to genetic vulnerabilities^{16, 17}.

Relatively little work describing genetic risk to COVID-19 severity has been conducted in community individuals with a full range of symptom severity. Thus, building on our previous work in the large sample of WTC responders who were infected with SARS-CoV-2, we investigated whether polygenic

vulnerabilities to COVID-19 hospitalization, as well as to asthma, related allergic diseases, coronary artery disease, and type II diabetes, were associated with COVID-19 severity and post-acute COVID-19 symptoms after adjusting for established risk factors. Based on previous findings, we hypothesized that PRS for COVID-19 hospitalization would significantly predict COVID-19 severity across a range of symptoms, and would help identify the most severe COVID-19 group. We tentatively hypothesized that PRS for asthma, allergic disease, coronary artery disease, and type II diabetes would predict worse COVID-19 severity outcomes and that the polygenic prediction would extend to development of post-acute COVID-19 sequelae.

Methods

Participants and Procedure

Participants were 983 WTC responders enrolled in a prospective cohort called the WTC Health Program which was established in 2002 and independently monitors the health of more than 13,000 WTC first responders living on Long Island, NY, USA¹⁸. The analytic sample comprised of all genotyped participants from an established cohort of responders with the first instance of SARS-CoV-2 infection before January 2022, with the median infection date of December 2020². The mean age of the analytic sample at infection was 56.06, SD=7.37, range= 39.79-89.04, 93.4% of the sample was male, and 82.3% had European ancestry. The analytic sample did not differ significantly from the total cohort of responders with SARS-CoV-2 infection (N=1,280) on demographic and symptom variables.

The analytic sample included responders with a verified history of a positive polymerase chain reaction, antigenic, or antibody test for SARS-CoV-2 or positivity for antibodies to SARS-CoV-2 nucleocapsid protein according to medical or laboratory records (N=587), as well as responders who reported a positive laboratory test for SARS-CoV-2, but for whom documented proof of the test results was not available (N=396). The unverified cases did not differ significantly from verified cases on all study variables, except for lower COVID-19 severity ($t(df)=2.30(847.60)$, $p=.02$, $d=.15$). Verifiable hospitalization records at local

hospitals increased the likelihood of objectively verifying the most severe responders. Analyses adjusted for verification status. All cases represent a first instance of SARS-CoV-2 infection.

Clinical information on initial and residual COVID-19 symptoms was collected irrespective of verification status through in-person questionnaires, surveys sent via email and text, electronic medical records obtained with the release of health information forms, and follow-up calls. Symptoms of COVID-19 in this study included respiratory symptoms (i.e., shortness of breath, chest pain, sore throat, congestion/runny nose, and wheezing), systemic symptoms (i.e., fever, fatigue, headache, chills, and weight loss), gastrointestinal symptoms (i.e., nausea, vomiting, and diarrhea), musculoskeletal symptoms (i.e., joint and muscle pain), central nervous system symptoms (i.e., dizziness, vertigo, loss of smell/taste, and brain fog), and psychiatric symptoms (i.e., anxiety, depression, and post-traumatic stress disorder [PTSD]).

Blood samples were drawn at the WTC Health Program clinic. The study was approved by the Institutional Reviewer Board of Stony Brook University, and all participants provided written informed consent. For more information on the study design, see Lhuillier, Yang ².

Measures

COVID-19 severity

Participants in the analytic sample were categorized into four severity groups according to their symptoms: asymptomatic ($N=92$, 9.4%), mild ($N=378$, 38.5%), moderate ($N=408$, 41.5%), and severe ($N=75$, 7.6%). This categorization was based on the NIH COVID-19 clinical spectrum updated October 2021 (National Institutes of Health, 2021). The asymptomatic category consisted of responders who reported a positive SARS-CoV-2 virologic test result without any symptoms associated with COVID-19. The mild category included responders with at least one symptom associated with COVID-19 but no shortness of breath or difficulty breathing. Moderate cases were in responders who reported shortness of breath and/or diagnosis of lower respiratory disease (pneumonia/bronchitis) during clinical assessment or imaging. These responders maintained oxygen saturation (SpO_2) $\geq 94\%$ on room air at sea level. Mild and moderate cases

were medically managed primarily at home, even if they initially visited a healthcare facility for medical treatment and/or testing. Severe cases included responders with SpO₂<93% on room air, respiratory rate >30 breaths/min, heart rate greater than 100 beats per minute, acute respiratory distress syndrome, septic shock, cardiac dysfunction, or an exaggerated inflammatory response in addition to pulmonary disease, or severe illness causing cardiac, hepatic, renal, central nervous system, or thrombotic disease during COVID-19. Responders were also categorized as severe if they were admitted to the hospital, or received intensive care or mechanical ventilation, or if they eventually died from COVID-19.

Post-acute COVID-19 symptoms

Residual symptoms were defined as any COVID-19-related symptoms that lasted at least 4 weeks after symptom onset (Centers for Disease Control and Prevention, 2021b). Residual symptoms included respiratory problems (e.g., dyspnea, chest discomfort, cough, and fatigue), CNS symptoms (e.g., loss or reduction of smell/taste, mental fog, dizziness, and vertigo), and musculoskeletal complaints. In the analytic sample, N=306 (31.1%) participants reported at least one residual COVID-19 symptom.

Covariates

Electronic medical records updated on January 1, 2020, were used to obtain date of birth to calculate age at infection, obstructive airway disease and upper respiratory disease diagnoses, and the most recent available measure of body mass index (BMI). Genetic data were used to obtain sex and ancestry information.

Genetic data processing and polygenic risk scores (PRS)

Genotyping of blood samples was performed at the Genomics Shared Resource at Roswell Park Cancer Institute, using the Infinium Global Screening Array (Illumina, San Diego, CA, USA), according to manufacturer protocols. Genotypes were imputed on the Michigan Imputation Server pipeline v1.2.4, using the Haplotype Reference Consortium reference panel¹⁹. Before imputation, the genotypes were filtered for ambiguous strand orientation, missingness rate>5% (by marker exclusion, then by individual), Hardy-Weinberg equilibrium violation ($p<10^{-6}$), and sex mismatch. After imputation, the single-nucleotide

polymorphisms (SNPs) were excluded for imputation $R^2 < 0.5$ and the average call rate below 90%. Genotype imputation was performed on 552,230 SNPs, resulting in 25,514,638 SNPs after quality control, which were used for matching to discovery GWAS variants for the final polygenic risk scoring.

PRS were created using PRSice 2.0²⁰. PRS were created by aggregating genetic variants up to varying thresholds of significance from a GWAS discovery sample, weighted by the associations in the discovery sample. Our primary analysis used a complete list of SNPs after clumping and their corresponding weights from GWAS discovery samples (P-value threshold=1) to incorporate more of the genome²¹. All analyses adjusted for the first ten genetic ancestry principal components (PCs). Primary analyses were conducted on participants of European ancestry due to the discovery GWAS being European; however, sensitivity analyses in the entire sample are also reported in the Supplementary Materials.

PRS for asthma and allergic disease were based on two GWAS conducted on participants of European ancestry from the UK Biobank²². The asthma GWAS was conducted in 90,853 individuals, 14,085 physician-diagnosed asthma cases, and 76,768 controls without asthma or allergic diseases. The allergic disease GWAS was conducted in 102,453 individuals, 25,685 with doctor-diagnosed hay fever, allergic rhinitis, eczema, or allergic asthma cases, and 76,768 controls without asthma or allergic disease.

The coronary artery disease PRS was based on a GWAS meta-analysis conducted in 122,733 coronary artery disease cases and 424,528 controls from the UK Biobank and the CARDIoGRAMplusC4D Consortium²³. Cases included patients with coronary artery disease diagnosis or treatment indicated in their electronic medical record or self-reported heart attack/myocardial infarction, coronary angioplasty, or heart bypass. The control group excluded participants who reported that their mother, father, or sibling suffered from heart disease. The type II diabetes PRS was based on a GWAS meta-analysis in 62,892 type II diabetes cases and 596,424 controls of European ancestry²⁴.

PRS for COVID-19 severity were based on summary statistics from two GWAS meta-analyses conducted by the COVID-19 Host Genetics Initiative⁹ release 6, dated June 15, 2021. This initiative is an international collaboration spanning 61 studies from 24 countries. The first GWAS was performed in 2,085,803 individuals, contrasting 24,274 patients hospitalized due to COVID-19 with 2,061,529 population controls presumed to be COVID-19 negative (COVID-PRS hospitalized vs. population). The second GWAS was conducted in 87,671 patients with COVID-19, contrasting 14,480 hospitalized patients with 73,191 non-hospitalized patients (COVID-PRS hospitalized vs. not-hospitalized).

Analytic approach

Linear regression was used to test whether PRS predict COVID-19 severity. Logistic regression was used to test whether PRS predict the severe category classification (severe vs. moderate/mild/asymptomatic), and the presence of post-acute COVID-19 symptoms. Variables were standardized prior to analysis. Models were adjusted for the first ten principal components of the population structure, COVID-19 verification status, age, and sex. Models testing asthma and allergic disease PRS were further adjusted for obstructive airway disease and upper respiratory disease diagnoses to ensure that associations do not merely reflect respiratory illness status. Likewise, models testing PRS for coronary artery disease and type II diabetes further adjusted for BMI. Models predicting residual symptoms additionally adjusted for COVID-19 severity. Separate models were conducted for each PRS. The primary analyses were conducted in participants of European ancestry. Given that COVID-19 GWAS were completed using multi-ancestry participants, for sensitivity testing and inclusivity results are also reported for participants of all ancestries in Supplementary Materials.

Role of the funding source

The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

Results

Descriptive statistics for the European ancestry sample are reported in Table 1. Many responders ($N=57$, 7.0%) had severe COVID-19. In total, 247 (30.4%) responders reported at least one residual COVID-19 symptom. Correlations between PRS are reported in Supplementary Table 1.

The PRS for asthma significantly predicted COVID-19 severity in the European ancestry subsample ($\beta=.09$, $p=.01$), independently of respiratory disease diagnoses, Table 2. Likewise, the PRS for asthma predicted COVID-19 severe category ($OR=1.61$, [1.17-2.21]). Allergic disease PRS showed a similar pattern, significantly predicting the COVID-19 severe category ($OR=1.97$, [1.26-3.07]). Associations with residual COVID-19 symptoms were not significant. There were no significant associations between coronary artery disease or type II diabetes PRS, and COVID-19 phenotypes (Table 3). The COVID-19 PRS based on the GWAS contrasting hospitalized cases vs. controls significantly predicted the COVID-19 severe category in sample with European ancestry ($OR=1.35$, [1.01-1.82]), Table 4. Conversely, the COVID-19 PRS based on the GWAS contrasting hospitalized cases vs. non-hospitalized cases did not reach significance in the European ancestry subsample. Moreover, none of the COVID-19 PRS predicted the full range of COVID-19 severity, nor the presence of any residual symptoms.

Sensitivity analyses

Descriptive statistics for total sample with participants of all ancestries are reported in Supplementary Table 2. In the total sample, adjusting for respiratory disease diagnoses, the PRS for asthma significantly predicted COVID-19 severity ($\beta=.08$, $p=.01$) and COVID-19 severe category ($OR=1.53$, [1.15-2.03]), and the allergic disease PRS predicted the COVID-19 severe category ($OR=1.86$, [1.25-2.77]), Supplementary Table 3. There were no significant associations between coronary artery disease or type II diabetes PRS, and COVID-19 phenotypes, Supplementary Table 4. The COVID-19 PRS based on the GWAS contrasting hospitalized cases vs. controls significantly predicted the COVID-19 severe category in the whole sample

($OR=1.42$, [1.11-1.82]), Supplementary Table 5. Likewise, the COVID-19 PRS based on the GWAS contrasting hospitalized cases vs. non-hospitalized cases also significantly predicted COVID-19 severe category in the total sample ($OR=1.33$, [1.04-1.69]).

Discussion

The current study reports associations between recently developed polygenic biomarkers and COVID-19 severity in a community-based population of responders to the WTC disaster who had COVID-19. We found that the PRS for asthma, allergic diseases, and COVID-19 severity were elevated in the severe COVID-19 category responders, which included responders with hospital admission, supplemental oxygen use, ICU admission, and death. Asthma PRS was also associated with COVID-19 symptomatology across the full spectrum of severity. No significant associations were observed for PRS for coronary artery disease and type II diabetes. Moreover, PRS did not predict post-acute COVID-19 sequelae. These findings add to the growing body of evidence to suggest that existing polygenetic profiles could be informative about the risk for severe COVID-19 presentation, despite the small effect sizes.

The current study is the first to report significant associations between asthma PRS and allergic disease PRS, and COVID-19 severity. A previous study in the UK Biobank found no association between asthma PRS and severe COVID-19¹⁴. However, the direction of association was positive, and asthma diagnosis was significantly associated with COVID-19 severity ($OR=1.39$), in line with epidemiological and clinical evidence⁷. In contrast to Zhu, Hasegawa¹⁴, in our subsample with European ancestry, the PRS for asthma was associated with a 1.61-fold increase in the odds of classification into the most severe COVID-19 category, as well as with the full range of COVID-19 symptom severity, independently of respiratory diagnoses. Moreover, the allergic disease PRS based on the related GWAS of cases with doctor-diagnosed hay fever, allergic rhinitis, eczema, or allergic asthma doubled the odds of classification into the most severe COVID-19 category in participants of European ancestry ($OR=1.97$), adjusting for demographic covariates and respiratory diagnoses. These results are consistent with the evidence for the role of immune function genes implicated in COVID-19 severity⁸. It is possible that asthma and allergic sensitization contribute to

the pathobiology of severe COVID-19, such as expression of the SARS-CoV-2 receptor ACE2^{25, 26}, and that asthma and allergic disease PRS capture these effects. Another possibility is that both asthma and atopic disease have a proclivity toward a TH2 immune response and thus may contribute to a TH1 or TH2 imbalance and a poorer outcome²⁷.

Contrary to our hypotheses, PRS for coronary artery disease and type II diabetes were not associated with any COVID-19 outcomes. Cardiovascular and other obesity-related disorders have previously been highlighted as risk factors for severe COVID-19 presentation and residual symptoms^{7, 28}, including in our sample². However, our findings suggest that genetic vulnerability to these conditions might not contribute prominently to COVID-19 severity. A study found a significant association between BMI PRS and higher risk of severe COVID-19 outcomes such as hospitalization; however, the effect sizes were small ($OR=1.14$)²⁹ and were below effect sizes the present study was powered to detect. Furthermore, the previous study did not find significant relationships between COVID-19 outcomes and PRS for BMI-adjusted waist-to-hip ratio and BMI-adjusted waist circumference, indicating an overall weak association between genetic vulnerability to high weight and COVID-19 severity, consistent with the current findings for PRS developed for coronary artery disease and type II diabetes.

The PRS based on the largest GWAS to date comparing hospitalized COVID-19 cases to healthy controls⁹ was significantly associated with a 1.35-fold increase in the odds of having had severe COVID-19. This finding agrees with previous studies based on large cohorts such as the UK Biobank which found that COVID-19 PRS were associated with severe COVID-19 outcomes¹⁰⁻¹². For example, Nakanishi, Pigazzini¹⁰ reported that COVID-19 PRS predicted death or severe respiratory failure ($OR=1.70$). Similarly, Horowitz, Kosmicki¹¹ reported that a PRS based on the top six SNPs associated with COVID-19 predicted a 1.38-fold increased risk of hospitalization and a 1.58-fold increased risk of severe disease in European ancestry participants, with results replicated in other ancestries. Importantly, COVID-19 severity PRS were not associated with the full spectrum of COVID-19 symptoms in our population and did not predict residual

post-acute COVID-19 syndrome. This finding adds novel evidence that the COVID-19 PRS specifically captures genetic vulnerability to a severe response to SARS-CoV-2 infection.

Strengths and Limitations

The strengths of the current study include a large sample with well-characterized COVID-19 symptomatology, follow-up information on post-acute COVID-19 sequelae, and application of PRS based on the largest discovery samples available for each disease. Nonetheless, we also note several limitations. First, the proportion of individuals with ancestry admixture in the WTC cohort is too small to allow genetic analyses in non-Northern European ancestries. Nonetheless, for transparency, we opted to report analyses in the total sample as well as the European ancestry subsample, and results are notably similar. In either sample, we were underpowered to detect very small associations. Relatedly, the WTC responder population is primarily male, and the number of females was insufficient to explore sex differences. Moreover, we were underpowered to stratify the sample by age, respiratory illness, or other characteristics related to COVID-19 severity. We have adjusted for these covariates in our analyses, but acknowledge that the findings arising from the current study may not generalize to other populations.

Second, some participants were included based on infection information that was not independently verified by the study team. However, these participants reported testing positive for SARS-CoV-2 through one of the available testing methods and did not differ from verified participants on any characteristics except COVID-19 severity, which is due to verified records being available for hospitalized responders, suggesting that misclassification was likely to be minimal. The COVID-19 verification status was included as a covariate in all analyses. Third, different viral strains and vaccination status can affect infection susceptibility and COVID-19 disease severity. We did not have sufficient data to investigate this issue, and future studies of PRS are needed to model complex interactions between these factors.

Conclusions

The current translational study found that PRS for asthma, allergic disease, and COVID-19 hospitalization were associated with an increased risk for severe COVID-19 presentation among community-based individuals infected with SARS-CoV-2. Asthma PRS was also associated with higher COVID-19 severity across the full range of symptoms. The current effect sizes were small, but with additional research, known genetic vulnerability factors might help to identify individuals at an increased risk for a severe course of COVID-19 disease.

Acknowledgements

The study was funded by CDC/NIOSH awards U01OH012275 to Drs. Luft and Morozova, and U01OH011864 to Drs. Waszczuk and Kotov. Additional support was provided by National Institute of Health awards R01MH123619 and R01MH123489 to Drs. Docherty and Shabalin. We would like to acknowledge ongoing funding to monitor World Trade Center responders as part of the WTC Health and Wellness Program (CDC 200-2011-39361). We thank participants for their commitment to the project. The findings and conclusions in this article are those of the authors and do not represent the official position of CDC. The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Data Availability Statement: Medical information is protected, so only processed de-identified data will be made available upon receipt of a written request to the corresponding author after the manuscript publication.

References

1. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of asthma and its genetic predisposition with the risk of severe COVID-19. *Journal of Allergy and Clinical Immunology*. 2020;**146**(2):327-9. e4.
2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *The Lancet infectious diseases*. 2020;**20**(5):533-4.
3. Lhuillier E, Yang Y, Morozova O, Clouston SA, Yang X, Waszczuk MA, et al. The Impact of World Trade Center Related Medical Conditions on the Severity of COVID-19 Disease and Its Long-Term Sequelae. *International Journal of Environmental Research and Public Health*. 2022;**19**(12):6963.
4. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. *Nature medicine*. 2021;**27**(4):601-15.
5. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. *JAMA network open*. 2021;**4**(10):e2128568-e.
6. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020;**584**(7821):430-6.
7. Ebinger JE, Achamallah N, Ji H, Claggett BL, Sun N, Botting P, et al. Pre-existing traits associated with Covid-19 illness severity. *PloS one*. 2020;**15**(7):e0236240.
8. Gao Yd, Ding M, Dong X, Zhang Jj, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: a review. *Allergy*. 2021;**76**(2):428-55.
9. Niemi ME, Daly MJ, Ganna A. The human genetic epidemiology of COVID-19. *Nature Reviews Genetics*. 2022:1-14.
10. COVID-19 Host Genetics Initiative. The COVID-19 host genetics initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. *European Journal of Human Genetics*. 2020;**28**(6):715.

11. Nakanishi T, Pigazzini S, Degenhardt F, Cordioli M, Butler-Laporte G, Maya-Miles D, et al. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. *The Journal of clinical investigation*. 2021;**131**(23).
12. Horowitz JE, Kosmicki JA, Damask A, Sharma D, Roberts GH, Justice AE, et al. Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease. *Nature genetics*. 2022;**54**(4):382-92.
13. Huang Q-M, Zhang P-D, Li Z-H, Zhou J-M, Liu D, Zhang X-R, et al. Genetic risk and chronic obstructive pulmonary disease independently predict the risk of incident severe COVID-19. *Annals of the American Thoracic Society*. 2022;**19**(1):58-65.
14. Crossfield SS, Chaddock NJ, Iles MM, Pujades-Rodriguez M, Morgan AW. Interplay between demographic, clinical and polygenic risk factors for severe COVID-19. *International Journal of Epidemiology*. 2022.
15. Morozova O, Clouston SA, Valentine J, Newman A, Carr M, Luft BJ. COVID-19 cumulative incidence, asymptomatic infections, and fatality in Long Island, NY, January–August 2020: A cohort of World Trade Center responders. *Plos one*. 2021;**16**(7):e0254713.
16. Waszczuk MA, Docherty AR, Shabalin AA, Miao J, Yang X, Kuan P-F, et al. Polygenic prediction of PTSD trajectories in 9/11 responders. *Psychological Medicine*. 2020:1-9.
17. Huckins LM, Johnson JS, Cancelmo L, Diab O, Schaffer J, Cahn L, et al. Polygenic regulation of PTSD severity and outcomes among World Trade Center responders. *medRxiv*. 2021:2020.12.06.20244772.
18. Dasaro CR, Holden WL, Berman KD, Crane MA, Kaplan JR, Lucchini RG, et al. Cohort Profile: World Trade Center Health Program General Responder Cohort. *International Journal of Epidemiology*. 2015.
19. McCarthy S, Das S, Kretschmar W, Delaneau O, Wood AR, Teumer A, et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nature genetics*. 2016;**48**(10):1279.

20. Euesden J, Lewis CM, O'Reilly PF. PRSice: polygenic risk score software. *Bioinformatics*. 2015;**31**(9):1466-8.
21. Wray NR, Lee SH, Mehta D, Vinkhuyzen AA, Dudbridge F, Middeldorp CM. Research review: polygenic methods and their application to psychiatric traits. *Journal of Child Psychology and Psychiatry*. 2014;**55**(10):1068-87.
22. Zhu Z, Lee PH, Chaffin MD, Chung W, Loh P-R, Lu Q, et al. A genome-wide cross-trait analysis from UK Biobank highlights the shared genetic architecture of asthma and allergic diseases. *Nature genetics*. 2018;**50**(6):857-64.
23. Van Der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. *Circulation research*. 2018;**122**(3):433-43.
24. Xue A, Wu Y, Zhu Z, Zhang F, Kemper KE, Zheng Z, et al. Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes. *Nature communications*. 2018;**9**(1):1-14.
25. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O'Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. *Journal of Allergy and Clinical Immunology*. 2020;**146**(1):203-6. e3.
26. Sajuthi SP, DeFord P, Li Y, Jackson ND, Montgomery MT, Everman JL, et al. Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium. *Nature communications*. 2020;**11**(1):1-18.
27. Gil-Etayo FJ, Suárez-Fernández P, Cabrera-Marante O, Arroyo D, Garcinuño S, Naranjo L, et al. T-helper cell subset response is a determining factor in COVID-19 progression. *Frontiers in cellular and infection microbiology*. 2021;**11**:624483.
28. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al. Association of obesity with disease severity among patients with coronavirus disease 2019. *Obesity*. 2020;**28**(7):1200-4.

29. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of obesity and its genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort data. *Metabolism*. 2020;**112**:154345.

Table 1 – Descriptive statistics for participants of European ancestry.

N total	813
N male (%)	772 (95.0%)
Mean age at infection (SD), range	56.06 (7.37), 39.79-89.04
N OAD diagnosis (%)	312 (38.4%)
N URD diagnosis (%)	525 (64.6%)
Mean BMI (SD), range	31.34 (5.08), 19.48-62.18
N COVID-19 severity (%)	
Asymptomatic	78 (9.6%)
Mild	320 (39.4%)
Moderate	332 (40.8%)
Severe	57 (7.0%)
Missing	26 (3.2%)
N any residual symptoms	247 (30.4%)

Notes:

OAD – Obstructive airway disease; URD – upper respiratory disease; BMI – body mass index;

COVID-19 – coronavirus disease 2019; SD - standard deviation.

Table 2– Associations between allergic disease and asthma PRS and COVID-19 severity and residual symptoms in participants of European ancestry.

	COVID-19 severity	COVID-19 severe category	Any residual symptoms
PRS: Asthma	$\beta=.09, p=.01$	OR=1.61 (CI: 1.17-2.21), $p<.01$	OR=1.07 (CI: .90-1.27), $p=.43$
PRS: Allergic disease	$\beta=.09, p=.06$	OR=1.97 (CI: 1.26-3.07), $p<.01$	OR=.89 (CI: .70-1.13), $p=.34$

Notes:

OR: Odds ratio; CI: 95% confidence interval; PRS: polygenic risk score; COVID-19: coronavirus disease 2019. All models are adjusted for the first ten principal components of the population structure, verification status, age at 9/11, sex, obstructive airway disease diagnosis, upper respiratory disease diagnosis. Models predicting residual symptoms were additionally adjusted for COVID-19 severity.

Table 3 – Associations between coronary artery disease and type II diabetes PRS and COVID-19 severity and residual symptoms in participants of European ancestry.

	COVID-19 severity	COVID-19 severe category	Any residual symptoms
PRS: Coronary artery disease	$\beta=.05, p=.21$	$OR=1.06$ (CI: .70-1.60), $p=.79$	$OR=1.22$ (CI: .97-1.53), $p=.09$
PRS: Type II diabetes	$\beta=.04, p=.32$	$OR=1.42$ (CI: .80-2.53), $p=.23$	$OR=.71$ (CI: .50-1.01), $p=.05$

Notes:

OR: Odds ratio; CI: 95% confidence interval; PRS: polygenic risk score; COVID-19: coronavirus disease 2019. All models are adjusted for the first ten principal components of the population structure, verification status, age at 9/11, sex, and BMI. Models predicting residual symptoms were additionally adjusted for COVID-19 severity.

Table 4 – Associations between COVID-19 PRS and COVID-19 severity and residual symptoms in participants of European ancestry.

	COVID-19 severity	COVID-19 severe category	Any residual symptoms
PRS: COVID-19 hospitalized vs. controls	$\beta=.03, p=.40$	OR=1.35 (CI: 1.01-1.82), p=.04	OR=1.11 (CI: .93-1.33), p=.24
PRS: COVID-19 hospitalized vs. not-hospitalized	$\beta=.05, p=.23$	OR=1.27 (CI: .95-1.69), p=.12	OR=1.08 (CI:.90-1.29), p=.41

Notes:

OR: Odds ratio; CI: 95% confidence interval; PRS: polygenic risk score; COVID-19: coronavirus disease 2019. All models are adjusted for the first ten principal components of the population structure, verification status, age at 9/11, and sex. Models predicting residual symptoms were additionally adjusted for COVID-19 severity.

Supplementary Materials

Supplementary Table 1 –Associations among PRS used in the study

	PRS: Asthma	PRS: Allergic disease	PRS: Coronary artery disease	PRS: Type II diabetes	PRS: COVID- 19 hospitalized vs. controls	PRS: COVID- 19 hospitalized vs. not- hospitalized
PRS: Asthma	1	.42*	.02	.04	.02	-.01
PRS: Allergic disease	.43*	1	-.03	-.01	.02	.00
PRS: Coronary artery disease	.02	-.02	1	.16*	.09*	.10*
PRS: Type II diabetes	.04	-.01	.16*	1	.12*	.03
PRS: COVID- 19 hospitalized vs. controls	.02	.03	.06	.10*	1	.63*
PRS: COVID- 19 hospitalized vs. not- hospitalized	.01	.01	.09*	.02	.65*	1

Note: Association in full sample reported below diagonal, associations in European ancestry reported above diagonal. Partial correlations adjusted for the first ten principal components of the population structure are reported.

* indicates $p < .05$

Supplementary Table 2 – Descriptive statistics for participants of all ancestries

N total	983
N male (%)	918 (93.4%)
Mean age at infection (SD), range	56.03 (7.37), 39.79-89.04
N OAD diagnosis (%)	372 (37.8%)
N URD diagnosis (%)	627 (63.8%)
Mean BMI (SD), range	31.31 (5.09), 19.48-62.18
N COVID-19 severity (%)	
Asymptomatic	92 (9.4%)
Mild	378 (38.5%)
Moderate	408 (41.5%)
Severe	75 (7.6%)
Missing	30 (3.1%)
N any residual symptoms	306 (31.1%)

Notes:

OAD – Obstructive airway disease; URD – upper respiratory disease; BMI – body mass index;

COVID-19 – coronavirus disease 2019; SD - standard deviation.

Supplementary Table 3– Associations between allergic disease and asthma PRS and COVID-19 severity and residual symptoms in participants of all ancestries.

	COVID-19 severity	COVID-19 severe category	Any residual symptoms
PRS: Asthma	$\beta=.08, p=.01$	OR=1.53 (CI:1.15-2.03), $p<.01$	OR=1.11 (CI:.95-1.29), $p=.20$
PRS: Allergic disease	$\beta=.09, p=.05$	OR=1.86 (CI: 1.25-2.77), $p<.01$	OR=.94 (CI: .75-1.18), $p=.59$

Notes:

OR: Odds ratio; CI: 95% confidence interval; PRS: polygenic risk score; COVID-19: coronavirus disease 2019. All models are adjusted for the first ten principal components of the population structure, verification status, age at 9/11, sex, obstructive airway disease diagnosis, upper respiratory disease diagnosis. Models predicting residual symptoms were additionally adjusted for COVID-19 severity.

Supplementary Table 4 – Associations between coronary artery disease and type II diabetes PRS and COVID-19 severity and residual symptoms in participants of all ancestries.

	COVID-19 severity	COVID-19 severe category	Any residual symptoms
PRS: Coronary artery disease	$\beta=.05, p=.24$	$OR=1.11$ (CI:.77-1.61), $p=.57$	$OR=1.19$ (CI:.96-1.47), $p=.12$
PRS: Type II diabetes	$\beta=.07, p=.27$	$OR=1.42$ (CI: .84-2.40), $p=.19$	$OR=.72$ (CI: .53-1.00), $p=.05$

Notes:

OR: Odds ratio; CI: 95% confidence interval; PRS: polygenic risk score; COVID-19:

coronavirus disease 2019. All models are adjusted for the first ten principal components of the population structure, verification status, age at 9/11, sex, and BMI. Models predicting residual symptoms were additionally adjusted for COVID-19 severity.

Supplementary Table 5 – Associations between COVID-19 PRS and COVID-19 severity and residual symptoms in participants of all ancestries.

	COVID-19 severity	COVID-19 severe category	Any residual symptoms
PRS: COVID-19 hospitalized vs. controls	$\beta=.04, p=.22$	OR=1.42 (CI:1.11-1.82), p=.01	OR=1.08 (CI: .92-1.26), p=.36
PRS: COVID-19 hospitalized vs. not-hospitalized	$\beta=.05, p=.15$	OR=1.33 (CI:1.04-1.69), p=.02	OR=1.05 (CI:.89-1.24), p=.55

Notes:

OR: Odds ratio; CI: 95% confidence interval; PRS: polygenic risk score; COVID-19: coronavirus disease 2019. All models are adjusted for the first ten principal components of the population structure, verification status, age at 9/11, and sex. Models predicting residual symptoms were additionally adjusted for COVID-19 severity.